Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer

This study aimed to evaluate the feasibility of and immune response to Wilms tumor gene 1 (WT1) peptide-pulsed dendritic cell vaccination combined with gemcitabine (DCGEM) as a first-line therapy among patients with advanced pancreatic cancer. Ten HLA-A*2402 patients were treated with WT1 peptide-pu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mayanagi, Shuhei, Kitago, Minoru, Sakurai, Toshiharu, Matsuda, Tatsuo, Fujita, Tomonobu, Higuchi, Hajime, Taguchi, Junichi, Takeuchi, Hiroya, Itano, Osamu, Aiura, Koichi, Hamamoto, Yasuo, Takaishi, Hiromasa, Okamoto, Masato, Sunamura, Makoto, Kawakami, Yutaka, Kitagawa, Yuko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409883/
https://www.ncbi.nlm.nih.gov/pubmed/25614082
http://dx.doi.org/10.1111/cas.12621

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409883/
https://www.ncbi.nlm.nih.gov/pubmed/25614082
http://dx.doi.org/10.1111/cas.12621

Ejemplares similares